PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-11.93%
Negative revenue growth while Drug Manufacturers - Specialty & Generic median is -0.42%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-15.04%
Negative gross profit growth while Drug Manufacturers - Specialty & Generic median is -11.18%. Seth Klarman would suspect poor product pricing or inefficient production.
-960.92%
Negative EBIT growth while Drug Manufacturers - Specialty & Generic median is -65.36%. Seth Klarman would check if external or internal factors caused the decline.
-1383.16%
Negative operating income growth while Drug Manufacturers - Specialty & Generic median is -42.52%. Seth Klarman would check if structural or cyclical issues are at play.
-825.75%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is -60.99%. Seth Klarman would investigate factors dragging net income down.
-782.35%
Negative EPS growth while Drug Manufacturers - Specialty & Generic median is -60.99%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-500.00%
Negative diluted EPS growth while Drug Manufacturers - Specialty & Generic median is -6.78%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
5.01%
Share growth above Drug Manufacturers - Specialty & Generic median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
5.01%
Diluted share growth above 2x Drug Manufacturers - Specialty & Generic median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
85.85%
OCF growth near Drug Manufacturers - Specialty & Generic median of 85.85%. Charlie Munger might attribute it to typical sector or cyclical patterns.
50.46%
FCF growth near Drug Manufacturers - Specialty & Generic median of 50.46%. Charlie Munger could consider this standard for the industry’s capex cycle.
21610.35%
10Y revenue/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.04%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
-58.90%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is -58.90%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
-34.59%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is -34.59%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
83.84%
OCF/share CAGR near Drug Manufacturers - Specialty & Generic median of 83.84%. Charlie Munger might attribute it to typical industry growth patterns.
96.51%
5Y OCF/share growth near Drug Manufacturers - Specialty & Generic median. Charlie Munger might attribute it to standard sector conditions for mid-term OCF expansions.
93.36%
3Y OCF/share growth near Drug Manufacturers - Specialty & Generic median. Charlie Munger would find it typical for industry-level short-term expansions.
-1432.24%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
-4510.94%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 54.48%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-1077.29%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 38.49%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
1098.12%
Equity/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 135.31% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
-52.70%
Negative 5Y equity/share growth while Drug Manufacturers - Specialty & Generic median is -52.70%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-68.46%
Negative 3Y equity/share growth while Drug Manufacturers - Specialty & Generic median is -68.46%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.31%
AR shrinking while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-0.98%
Decreasing inventory while Drug Manufacturers - Specialty & Generic is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-18.81%
Assets shrink while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-25.50%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is -25.50%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-7.99%
Debt is shrinking while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman might see an advantage if growth remains possible.
41.67%
R&D growth of 41.67% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
-14.49%
SG&A decline while Drug Manufacturers - Specialty & Generic grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.